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Philipp Yorck Herzberg,1 Pia Heussner,2 Friederike H. A. Mumm,2 Melanie Horak,2
Inken Hilgendorf,3 Stephanie von Harsdorf,4 Philipp Hemmati,5 Kathrin Rieger,6
Hildegard Greinix,7 Mathias Freund,3 Stephanie J. Lee,8 Ernst Holler,9 Daniel Wolff9Chronic graft-versus-host disease (cGVHD) associated morbidity and mortality remain major barriers for
successful allogeneic hematopoietic stem cell transplantation (alloHSCT). Currently, no reliable measures
are established to monitor cGVHD activity changes for use in clinical trials. The Human Activity Profile
(HAP) patient self-report was proposed by the National Institutes of Health (NIH) cGVHD consensus pro-
ject as an independent measure of patients’ functional status that could also indirectly reflect improvement of
cGVHD, but that has not been validated in an alloHSCT patient population. One hundred seventy-six patients
(median age 44 years [range: 18-72 years] after alloHSCTwere evaluated with a German translation of the
HAP, the NIH criteria-based cGVHD activity assessment, the Lee cGVHD Symptom-Scale, FACT-BMT, SF36,
Berlin Social Support Scale, 24-Item Adjective Measure (24-AM), Hospital Anxiety and Depression Scale, and
the NCCN-Distress-Thermometer. Enrollment occurred a median of 286 (range: 85-4003) days after
alloHSCT. Follow-up surveys were conducted at 1, 2, 3, 5, 8, and 12 months after the baseline survey.
Although 117 patient had cGVHD at time of enrollment (mild n 5 33, moderate n 5 50, or severe
n 5 34), 59 patients were included into the study in the absence of cGVHD between days 85 and 395 after
transplantation. The maximum activity score (MAS) and adjusted activity score (AAS) of the HAP correlated
inversely with grading of cGVHD severity (mild, moderate, or severe) (r 5 20.25 for MAS and 20.24 for
AAS). Lung manifestations of cGVHD correlated with AAS (r 5 0.17), but not with MAS. HAP scores cor-
related with subscales from other instruments measuring physical domains, especially the physical functioning
scale of the SF36. Performance was improved by use of an HSCT-modified HAP scoring system that excluded
activities prohibited within the first year after alloHSCT. No significant correlation of the HAP was found
with personality, age, sex, symptom burden, or social functioning or social well-being. Moreover, the HAP
displayed a higher sensitivity to change of cGVHD activity compared to the SF36 and the FACT-BMT. In ad-
dition, steroid myopathy correlated with both HAP scores, but not the SF36. The HAP is a simple and valid
questionnaire for the evaluation of the physical activity in patients after alloHSCT, with the advantage of de-
tecting changes in cGVHD status independently of other quality-of-life measures and with a superior sensi-
tivity compared to the SF36.
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Chronic graft-versus-host disease (cGVHD) is the
leading cause for late morbidity and mortality after
allogeneic hematopoietic stem cell transplantation
(alloHSCT) [1,2]. Moreover, cGVHD is associated
with a significant impact on quality of life (QOL)
[3-6]. Health-related QOL is a multidimensional con-
struct that includes broad domains such as emotional,
physical, social, financial, and spiritual well-being, is
dynamic, and can be influenced by a myriad of factors.
Therefore, although QOL is an important issue in
chronically ill patients, its use as the sole endpoint in
clinical studies may be limited by its multifactorial
nature. An important aspect in QOL is the functional
capacity of patients, which is less dependent on multidi-
mensional factors than global assessment of QOL.
Although some QOL questionnaires include physical
domains, such as the SF36 and the FACT, these tools
are relatively insensitive to minor but relevant changes
and do not allow detailed measurements of the activity
profile of patients [7].
The Human Activity Profile (HAP) is a 94-item self-
reported assessment of energy expenditure or physical
fitness that was developed by Daughton et al. [8] in
a population of patients with pulmonary disease. The
HAP is easy to complete and has been used in a variety
of diseases like chronic fatigue syndrome, multiple scle-
rosis, chronic renal failure, and inflammatory synovitis
[9-11], and correlates with the physical functioning
scale of the SF36 [12]. Because of its coverage of a broad
range of activities and its high test-retest correlation in
other patient populations, it has been suggested by the
National Institutes of Health (NIH) Consensus Devel-
opment Project on Criteria for Clinical Trials in
cGVHD for measurement of the functional outcomes
of patients in clinical trials [12,13]. Because the HAP
has not been validated in patients after alloHSCT, the
present study was performed in a population of
patients after alloHSCT with and without cGVHD. A
secondary aim was the validation of the questionnaire
after translation into the German language.PATIENTS AND METHODS
Patients
The validation of the HAP was performed as part
of a prospective multicenter study evaluating the
NIH recommended data collection instruments after
translation into the German language [13,14].
Additional aims of the study were to prospectively
validate the NIH severity grading, the NIH patient
self-assessment instruments, and the German transla-
tions of the FACT-BMT and cGVHD Symptom-
Scale (L-cGVHD-SC) questionnaires. The study was
reviewed and approved by an institutional reviewboard at each center. Patients were enrolled during
regular visits at the transplant center after informed
consent between day 100 and 1 year after alloHSCT,
or in the presence of active cGVHD requiring immu-
nosuppressive treatment after day 100 without time
limit (inclusion criteria). Exclusion criteria were life
expectancy \3 months, inability to understand and
fill out the forms without assistance, or relapse of the
underlying malignancy. Patients without cGVHD
were included for validation of the HAP and FACT-
BMT to control for time-dependent effects after
alloHSCT and to detect the effect of comorbidities in-
dependent of cGVHD. All patients were informed that
patients and caregivers were not given the individual
results of the study evaluations.Data Collection Instruments and Methods
All patients included were evaluated according to
the NIH criteria-based cGVHD activity assessment
form [13], the German versions of the L-cGVHD-SC
[15], FACT-BMT [16], HAP, SF36 [17], Berlin Social
Support Scale (BSSS) [18], 24-Item Adjective Measure
(24-AM, measuring personality) [19], Hospital Anxiety
and Depression Scale (HADS) [20,21], and the
NCCN-Distress-Thermometer [22,23]. Follow-up
surveys were conducted at 1, 2, 3, 5, 8, and 12 months
after the baseline survey. At all time points cGVHD
severity assessment (NIH cGVHD staging form),
disease status, comorbidities, and medication were
documented by the care-giving physician [14]. The
cGVHD overall response assessment was collected by
the 10-point scale for severity assessment and 7-point
scale for response assessment proposed by the NIH
consensus conference on cGVHD [13]. Comorbidities
were defined according to their impact on daily
activities or clinical relevance. Steroid-myopathy was
grouped into absent (no symptoms), mild (mild to
moderate interference with daily activity), and severe
(requiring wheelchair or unable to get up with exter-
nal assistance). Additionally, the NIH-Symptom-Scale
was collected for clinician’s rating of cGVHD symp-
toms [14].
The HAP is a 94-item questionnaire with a list of
94 specific activities ranked according to the energy
expenditure required to perform the task. The respon-
dents are asked to indicate, whether they are ‘‘still do-
ing this activity,’’ have ‘‘stopped doing this activity,’’ or
‘‘never did this activity.’’ Two scores are calculated: the
maximum activity score (MAS), which is the number of
the most difficult task the respondent is ‘‘still doing.’’
The adjusted activity score (AAS) is calculated by
counting how many activities with lower values than
the maximum activity score the respondent has
‘‘stopped doing’’ and subtracting this from the MAS.
The latter score is considered a more stable estimate
of the individual’s daily activity compared to the MAS.
Table 1. Patients Characteristics
Whole Cohort (n 5 176)
Patients with
cGVHD (n 5 117)
Patients without
cGVHD (n 5 59)
Median age in years (range) 44 (18-72) 44 (21-72) 44 (18-67)
Sex: Male n 92 65 27
Female n 84 52 32
Median interval from alloHSCT to inclusion in days (range) 286 (85-4003) 438 (100-4003) 145 (day 85-392)
Prior aGVHD n (%) 104 (59%) 78 (66%) 26 (44%)
Severity of cGVHD at time of inclusion mild n 5 33
moderate n 5 50
severe n 5 34
Histologic confirmation of cGVHD n (%) 57 (49%)
cGHVD indicates chronic graft-versus-host disease; aGVHD 5 acute graft-versus-host disease; HSCT, hematopoietic stem cell transplantation.
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a professional translators bureau experienced in transla-
tion of QOL questionnaires from the original English
version and crosschecked by multiple bidirectional
translations for accuracy of the translated version.
Biostatistical Methods
Data were analyzed with the Statistical Package for
Social Sciences 15.0 (SPSS, Inc., Chicago, IL) and
checked for normality and homogeneity of variance
prior to analysis. Furthermore, all study variables
were examined through various SPSS programs for ac-
curacy of data entry, missing values, and fit of their dis-
tribution and the assumptions of multivariate analysis.
Pair-wise linearity was checked using scatterplots and
was found to be satisfactory. Nonindependence among
assessments per patient was considered by choosing
the appropriate statistical procedures (eg, repeated
measurement analysis). Descriptive statistics including
means, standard deviations, frequencies, percentages,
and ranges were calculated for sociodemographic and
study variables. Multivariate analyses included hierar-
chical multiple regression analysis, and for sensitivity
to change analyses, repeated measurement analysis
and log-linear analyses were used. Stepwise multiple
regression was used to evaluate independent predictors
of the MAS and AAS. Log-linear models were used to
analyze the sensitivity to change analyses of 2 or more
categorical values, whereas repeated measurement
analysis was used to analyze the sensitivity to change
of continuous variables. Interpretation of the correla-
tion magnitude is according to the recommendation
of Cohen [24], which classifies correlations below
0.10 as small, below 0.30 as moderate, and .0.50 as
large. Statistical significance for all analyses was estab-
lished when a 2-tailed P-value was\.01.RESULTS
Patients Characteristics
One hundred eighty-three patients from 5 German
and 1 Austrian transplant centers were included in thestudy. Complete data were provided by 176 patients
as shown in Table 1. The median age at time of enroll-
ment was 44 (range: 18-72) years. All but 4 patients
received an alloHSCT for hematologic malignancies.
The remaining 4 patients received an alloHSCT for
treatment of aplastic anemia (n 5 3) or paroxysmal
nocturnal hemoglobinuria (n5 1). Eighty-four patients
were females and 92 were males. One hundred four pa-
tients (59%) had a history of acute GVHD (aGVHD),
whereas 72 did not. One hundred seventeen patients
had classic cGVHD at time of enrollment (mild, n 5
33; moderate, n 5 50; or severe, n 5 34) as shown in
Table 2. Fifty-nine patients were included in the study
in the absence of cGVHD. The median day of inclusion
in the study was day 286 posttransplantation (range: 85-
4003 days). Two patients were included before day 100
(day 85 and day 96) (protocol violation) but were left in
the evaluation because of the fact that all other evalua-
tions were performed within the proposed time frame.
Sixty-four patients received alloHSCTs from HLA-
identical siblings, 81 from HLA-identical unrelated do-
nors, 5 from HLA-mismatched related donors, 20 from
HLA-mismatched unrelated donors, and 6 from hap-
loidentical related donors. Forty-one patients had low
platelets at time of diagnosis of cGVHD. Twenty-
four patients with cGVHD had direct progression of
aGVHD into cGVHD (progressive onset). The de-
tailed patient characteristics are displayed in Tables 1
and 2.Psychometric Testing of the HAP
Data were analyzed with the Statistical Package for
Social Sciences (SPSS, Inc.) and checked for normality
and homogeneity of variance prior to analysis. The
item statistics for the HAP are reported in Table 3.
Most obvious are the low corrected item-scale correla-
tions (rit) for the first 6 items indicating that only\5%
of patients stopped doing an activity listed in the first 6
items. Psychometric properties of the MAS and the
AAS are given in Table 4. Although the scales have sta-
tistically significant Kolmogorov-Smirnov Z-scores,
values\3.0 are considered as approximately normally
distributed [25]. Internal consistency (index of the
Table 2. Organ Involvement and Severity of cGVHD at Time
of Inclusion (n 5 117)
Organ/Severity None Mild Moderate Severe
Skin 33 38 32 14
Oral 43 56 15 3
Eye 47 44 23 3
Liver 69 40 4 4
Gastrointestinal 83 27 7 0
Genital 0 5 3 4
Lung 80 24 11 2
Fascia/joints 92 14 9 2
1710 Biol Blood Marrow Transplant 16:1707-1717, 2010P. Y. Herzberg et al.extent to which all of the items in a test measure the
same latent variable) for the MAS scores was high
(Cronbachs’s alpha 0.96), split half reliability for 2
test halves with 47 items each was 0.75 (Guttman’s
split half coefficient) with a correlation of 0.68 between
both subsets, indicating very good reliability of the
scale. Correlation between MAS and AAS was 0.86,
P \ .001. The test-retest correlations for MAS and
AAS scores for successive monthly time intervals
are 0.45 and 0.66 for month 1, .38 and .66 for month
2, and 0.48 and 0.71 for month 3, for MAS and AAS,
respectively. The test-retest correlation analysis was
restricted to monthly intervals to reduce the variability
of HAP results because of changes in the GVHD and/
or comorbidity status.
Because the HAP asks about specific activities in-
cluding tasks typically not permitted while patients
are on immunosuppression because they may increase
the risk of infection, we developed a hematopoietic
stem cell transplant adjusted AAS (HSCT-adjusted
AAS). A list of several activities typically prohibited
or restricted in patients receiving systemic immuno-
suppression was generated and compared with the in-
dividual results of the items on the HAP. If 1 of these
items was answered with ‘‘have stopped doing this ac-
tivity‘‘ despite being more than 5 items below the MAS
in more than one-third of the patients, the item was
excluded from the analysis of the HSCT-adjusted
AAS. In addition, the activities 72-73 (shoveling/dig-
ging) and 77-78 (swimming) were excluded solely be-
cause of the fact that these activities are typically
prohibited in patients receiving immunosuppression
after alloHSCT. Applying this approach, 20 items
were identified: 11 (dining in a restaurant), 15 (attend-
ing a movie/church), 19-20 (using public transporta-
tion or driving car), 22 (washing and drying dishes),
25 (dusting/polishing furniture or polishing a car), 34
(cleaning windows), 41 (shopping by yourself), 42
(washing clothes), 47 (scrubbing), 49-50 (sweeping),
52-54 (vacuuming and painting), 57 (carrying out gar-
bage), 72-73 (shoveling/digging), and 77-78 (swim-
ming). Therefore, we calculated the HSCT-adjusted
AAS excluding the above mentioned activities (11,
15, 19-20, 22, 25, 34, 41, 42, 47, 49, 50, 52-54, 57,
72-73, and 77-78) by subtraction from the MAS ifthese were answered with ’’stopped doing this activ-
ity.’’ Evaluation of the HSCT-adjusted AAS revealed
that this phenomenon was more prominent during
the first year after transplantation, T 5 16, P\ .001
(mean AAS 55, mean HSCT-adjusted AAS 63) but re-
mained significant at a lower level after 1 year post-
transplantation, T 5 13, P \ .001 (mean AAS 56,
mean HSCT-adjusted AAS 63). Moreover, the differ-
ence between the AAS and HSCT-adjusted AAS was
most prominent in the cohort of patients having no
cGVHD during the first year after transplantation
resulting in a statistically significant higher HSCT-
adjusted AAS compared to the AAS (P 5 .04).
Validity
Convergent validity
Convergent validity tests whether constructs that
are expected from theory to be related to the endpoint
of the questionnaire are, in fact, related. Table 5 shows
the correlation between the HAP and different global
and disease specific measures of QOL as measured by
the SF36, FACT-BMT, and cGVHD Symptom-
Scale. Consistent with prior publications, the factors
measuring physical domains were correlated most
closely with the HAP scales, especially the physical
functioning scale of the SF36. The correlation of
global grading of cGVHD severity (mild, moderate,
or severe) according to the NIH criteria with the
HAP reached statistical significance (r 5 20.25 for
MAS and 20.24 for AAS, Ps\ .01); lung involvement
of cGVHD correlated inversely with the AAS (r 5
0.17, P\ .05) but not with the MAS (r 5 0.13 P .
.05). The association of cGVHD severity with the
MAS and AAS are shown in Figures 1 and 2. The
HSCT-adjusted AAS score correlated significantly
with global assessment of cGVHD severity (r 5
20.26, P\ .01), with lung involvement of cGVHD
(r 5 0.18, P \ .05), and with all subscales of the
SF36. Although initially not expected, anxiety and de-
pression as measured by the HADS was moderately
correlated with both HAP scores (r . 20.20 for anxi-
ety, and r $ 20.40 for depression). Clinically signifi-
cant depression (HADS score .10) was reported by
21 patients (12%) and moderate depression (HADS
score 8-10) was present in additional 30 patients
(18%).
Discriminant validity
Discriminant validity tests whether constructs that
are expected from theory not to be related to the end-
point of the questionnaire are, in fact, not related.
Table 5 (lower panel) also shows the correlation
between the HAP and measures not theoretically
correlated. No significant correlation was found with
personality as measured by the 24-AM, which covers
the Big Five personality dimensions. Moreover, social
Table 3. Psychometric Testing of the HAP: Means, Standard Deviations and Item-Scale Correlation
Activity M SD rit
1. Getting in and out of chairs or bed (without assistance) 1.03 0.58 .21
2. Listening to the radio 1.01 0.58 .02
3. Reading books, magazines, or newspapers 1.02 0.61 .21
4. Writing (letters, notes) 1.06 0.61 .31
5. Working at a desk or table 1.11 0.60 .31
6. Standing (#1 min) 1.02 0.60 .33
7. Standing (#5 min) 1.11 0.68 .53
8. Dressing or undressing (without assistance) 1.05 0.40 .37
9. Getting clothes from drawers or closets 1.02 0.44 .21
10. Getting in or out of a car (without assistance) 1.02 0.52 .41
11. Dining at a restaurant 1.24 0.51 .52
12. Playing cards/table games 1.26 0.49 .30
13. Taking a bath (without assistance) 1.15 0.54 .46
14. Putting on shoes, stockings, or socks (no rest/break needed) 1.07 0.54 .31
15. Attending a movie, play, church event or sports activity 1.34 0.56 .56
16. Walking 30 yards 1.04 0.49 .42
17. Walking 30 yards (nonstop) 1.04 0.53 .43
18. Dressing/undressing (no rest/break needed) 1.11 0.57 .47
19. Using public transport or driving a car (#99 miles) 1.18 0.64 .53
20. Using public transport or driving a car (#110 miles) 1.42 0.63 .57
21. Cooking your own meals 1.15 0.76 .41
22. Washing or drying dishes 1.17 0.64 .41
23. Putting groceries on shelves 1.12 0.63 .27
24. Ironing or folding clothes 1.60 0.58 .26
25. Dusting/polishing furniture or polishing car 1.67 0.63 .44
26. Showering 1.03 0.61 .19
27. Climbing 6 steps 1.03 0.58 .24
28. Climbing 6 steps (nonstop) 1.06 0.62 .43
29. Climbing 9 steps 1.07 0.59 .44
30. Climbing 12 steps 1.10 0.57 .57
31. Walking half a block on level ground 1.03 0.57 .31
32. Walking half a block on level ground (nonstop) 1.09 0.54 .57
33. Making a bed (not changing sheets) 1.21 0.55 .36
34. Cleaning windows 1.78 0.55 .42
35. Kneeling or squatting to do light work 1.35 0.57 .61
36. Carrying a light load of groceries 1.09 0.56 .56
37. Climbing 9 steps (nonstop) 1.10 0.56 .55
38. Climbing 12 steps (nonstop) 1.14 0.58 .56
39. Walking half a block uphill 1.18 0.57 .52
40. Walking half a block uphill (nonstop) 1.32 0.61 .57
41. Shopping (by yourself) 1.18 0.57 .53
42. Washing clothes (by yourself) 1.58 0.57 .26
43. Walking 1 block on level ground 1.09 0.57 .46
44. Walking 2 blocks on level ground 1.14 0.56 .66
45. Walking 1 block on level ground (nonstop) 1.15 0.58 .67
46. Walking 2 blocks on level ground (nonstop) 1.16 0.56 .68
47. Scrubbing (doors, walls or cars) 1.59 0.52 .57
48. Making beds (changing sheets) 1.33 0.58 .46
49. Sweeping 1.37 0.58 .43
50. Sweeping (5 min nonstop) 1.47 0.61 .47
51. Carrying a large suitcase or bowling (1 line) 1.69 0.61 .55
52. Vacuuming carpets 1.48 0.60 .48
53. Vacuuming carpets (5 minutes nonstop) 1.54 0.60 .53
54. Painting (interior/exterior) 2.05 0.68 .42
55. Walking 6 blocks on level ground 1.20 0.40 .64
56. Walking 6 blocks on level ground (nonstop) 1.27 0.44 .65
57. Carrying out the garbage 1.37 0.52 .46
58. Carrying a heavy load of groceries 1.54 0.51 .55
59. Climbing 24 steps 1.25 0.49 .62
60. Climbing 36 steps 1.36 0.54 .66
61. Climbing 24 steps (nonstop) 1.40 0.54 .61
62. Climbing 36 steps (nonstop) 1.53 0.56 .63
63. Climbing walking 1 mile 1.29 0.49 .68
64. Climbing walking 1 mile (nonstop) 1.44 0.53 .66
65. Running 110 yards or playing softball/baseball 1.89 0.57 .54
66. Dancing (social) 1.77 0.64 .46
67. Doing callisthenics/aerobics(5 minutes nonstop) 1.63 0.63 .47
68. Mowing the lawn (not riding mower) 1.96 0.76 .29
69. Walking 2 miles 1.54 0.64 .68
70. Walking 2 miles (nonstop) 1.65 0.63 .61
71. Climbing 50 steps 1.49 0.58 .71
(Continued )
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Table 3. (Continued )
Activity M SD rit
72. Shoveling, digging, or spading 1.91 0.63 .35
73. Shoveling, digging, or spading (5 minutes nonstop) 1.95 0.61 .34
74. Climbing 50 steps (nonstop) 1.69 0.58 .61
75. Walking 3 miles or golfing 18 holes 1.68 0.62 .57
76. Walking 3 miles (nonstop) 1.81 0.59 .51
77. Swimming 25 yards 1.81 0.57 .51
78. Swimming 25 yards (nonstop) 1.83 0.57 .52
79. Bicycling 1 mile 1.45 0.54 .58
80. Bicycling 2 miles 1.49 0.55 .59
81. Bicycling 1 mile (nonstop) 1.49 0.55 .63
82. Bicycling 2 miles (nonstop) 1.57 0.57 .61
83. Running or jogging 0.25 mile 2.02 0.56 .56
84. Running or jogging 0.5 mile 2.09 0.56 .55
85. Playing tennis or racquetball 2.31 0.58 .39
86. Playing basketball (game play) 2.30 0.57 .42
87. Running or jogging 0.25 mile (nonstop) 2.09 0.61 .55
88. Running or jogging 0.5 mile (nonstop) 2.16 0.57 .55
89. Running or jogging 1 mile 2.16 0.57 .53
90. Running or jogging 2 miles 2.20 0.57 .54
91. Running or jogging 3 miles 2.26 0.56 .46
92. Running or jogging 2 miles in #12 min 2.25 0.58 .49
93. Running or jogging 2 miles in #20 min 2.26 0.56 .48
94. Running or jogging 2 miles in #30 min 2.31 0.52 .39
HAP indicates Human Activity Profile.
1712 Biol Blood Marrow Transplant 16:1707-1717, 2010P. Y. Herzberg et al.functioning and social well-being are not significantly
correlated with the HAP. Interestingly, we did not
find a correlation with symptom burden including the
eye and skin subscale of the cGVHD Symptom-Scale.
Not in accordance with prior hypotheses is the fact
that patients’ self-assessed (mild, moderate, or severe)
cGVHD severity at baseline is not related to the HAP
scores. Furthermore, age and sex were not correlated
with both HAP scores. We also undertook multivariate
regression analyses to examine the overlap of the con-
vergent measures of QOL (SF36, FACT-BMT, and
cGVHD Symptom-Scale). The strongest predictor of
the MAS was the FACT-G total score (b 5 20.38,
P\ .001), followed by the general health perception
score of the SF36 (b 5 0.15, P \ .05), whereas the
cGVHD Symptom-Scale total score was not predictive
of the MAS (b 5 20.12, P . .05). The model was sig-
nificant, F (3, 162)5 17.1, P\ .001, and accounted for
23% of the variance. The fact that the cGVHD
Symptom-Scale total score was only predictive in uni-
variate analyses but not when entered together with
the FACT-G total score results from the large overlap
of both questionnaires. The correlation between
FACT-G total score and the cGVHD Symptom-Table 4. Psychometric Properties of the Human Activity Profile (H
Score M SD
Maximum Activity Score MAS 73.25 17.70
Adjusted Activity Score AAS 56.39 20.63
Modified Activity Score AAS 63.47 19.35
K-S indicates Kolmogoroff-Smirnov Z-value; MAS, maximum activity score; AA
*P < .05.
***P < .001Scale total score was 0.63, indicating a 40% variance
overlap of both scores. The strongest predictor of
AAS was again the FACT-G total score (b 5 20.53,
P\ .001), whereas neither the general health percep-
tion score of the SF36 (b 5 0.12, P . .05) nor the
Lee symptom total score (b 5 20.10, P . .05) were
predictive of the AAS. The model was significant,
F (3, 162) 5 31.6, p\ .001, and accounted for 36%
of the variance.
We also conducted regression analyses in which
the subscales were entered instead of the total scores.
For MAS, the amount of explained variance was
.49%. Table 6 presents the results of the regression
analyses. For AAS the amount of explained variance
was .69%. The strongest predictor for both scores
was the physical functioning scale of the SF36 and
the Energy subscale of the cGVHD Symptom-Scale.
Only the functional well-being scale of the FACT-
BMT added to the prediction of the MAS beyond
the physical functioning scale, whereas none of the
remaining subscales reached statistical significance in
the prediction of the AAS.
With regard to the impact of comorbidity, the pres-
ence of steroid-myopathy (as judged by the physicianAP)
Skewness Kurtosis K-S a
22.07 5.37 2.80*** .96
20.71 0.15 1.38* —
21.19 1.54 1.53* —
S, adjusted activity score.
Table 5. Correlations between HAP and Age, Sex, the SF-36,
FACT-BMT, and Lee-Symptom Scale Domains, cGVHD Se-
verity Assessments, and the HADS
MAS AAS Mod AAS
Age 20.20 20.22 20.24
Sex 0.16 0.15 0.16
SF-36
Bodily pain 0.33 0.47 0.43
Mental health 20.34 20.48 20.46
Physical functioning 0.61 0.78 0.77
Role limitation physical 0.47 0.62 0.59
Role limitation emotional 0.26 0.46 0.40
Social functioning 0.11 0.21 0.19
Vitality 0.32 0.42 0.42
Change in health 0.30 0.38 0.38
General health perception 0.19 0.15 0.15
FACT-BMT
Physical well-being 20.42 20.59 20.56
Social well-being 20.06 20.18 20.16
Emotional well-being 20.33 20.42 20.40
Functional well-being 20.39 20.53 20.50
FACT-G total score 20.40 20.56 20.53
Lee-Symptom Scale
Summary symptoms 20.35 20.42 20.43
Energy 20.38 20.51 20.51
Skin 20.17 20.16 20.19
Nutrition 20.22 20.23 20.22
Lung 20.29 20.39 20.39
Psychologic 20.19 20.25 20.23
Mouth 20.15 20.16 20.20
Eye 20.20 20.22 20.23
cGVHD severity 20.08 20.11 20.13
Global assessment of cGVHD severity 20.25 20.24 20.26
Lung 0.13 0.17 0.18
Anxiety 20.21 20.28 20.27
Depression 20.40 20.52 20.51
Discriminant validity
Neuroticism 20.09 20.13 20.11
Extraversion 0.04 0.08 0.06
Openness to experience 20.03 20.08 20.09
Agreeableness 20.09 20.09 20.11
Conscientiousness 0.12 0.11 0.12
HAP indicates Human Activity Profile; cGVHD, chronic graft-versus-
host disease; HADS, Hospital Anxiety and Depression Scale; MAS,
maximum activity score; AAS, adjusted activity score.
Note: Correlations > j.24j are significant at P < .001 and > j.15j are
significant at P < .05. (2-tailed).
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Figure 1. Influence of cGVHD severity according to the NIH Consen-
sus (1 5 mild, 2 5 moderate, or 3 5 severe) on the adjusted activity
score (AAS).
erevesetaredomdlim
60
65
70
75
80
M
A
S
Figure 2. Influence of cGVHD severity according to the NIH Consen-
sus (1 5 mild, 2 5 moderate, or 3 5 severe) on the maximum activity
score (MAS).
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with steroids) (n 5 31) was significantly associated
(P\ .001) with the MAS, AAS, and HSCT-adjusted
AAS because patients having steroid-myopathy had
a significantly lower MAS score of 63 compared to pa-
tients without steroid-myopathy with MAS of 76. The
same applied to the AAS (39 versus 60) and HSCT-
adjusted AAS (48 versus 67). Steroid-myopathy (SM)
was also significantly related to the physical function-
ing scale of the SF36 (52 without SM versus 21.2 in
the presence of SM; P\ .001) and to the functional
well-being scale of the FACT (2.6 without SM versus
3.3 in the presence of SM; P\ .001) In contrast to
steroid-myopathy, the presence of symptomatic osteo-
porosis and osteonecrosis or daily muscle cramping was
not associated with the MAS or AAS. Moreover, the
time after transplantation had no significant impact
on the MAS or AAS (P. .05).Sensitivity to Change
To test whether changes in cGVHD status were
associated with physical functioning, patients were
divided into 4 groups according to the change of the
overall severity of cGVHD. Only patients in whom
complete cGVHD grading was available for all time
points were included in the analysis. The analysis
was performed for a 5-month interval (comparison of
overall severity of cGVHD at time of enrollment
versus follow-up visit 5 months after enrollment).
The 5-month interval was chosen because response
Table 6. Hierarchical Multiple Regression Analyses Predict-
ing Maximum Activity Score, Adjusted Activity Score, and
Modified Adjusted Activity Score
Score
HAP AAS Mod AAS
B b B
SF-36
Bodily pain 20.04 20.03 20.19
Mental health 0.07 0.16 0.08
Physical functioning 0.78*** 0.75*** 0.75
Role limitation physical 0.07 0.05 0.34***
Role limitation emotional 20.05 0.13 0.05
Social functioning 20.03 0.05 20.04
Vitality 0.00 20.06 0.05
Change in health 20.11 20.02 0.00
FACT-BMT
Physical well-being 0.20 20.01 20.01
Social well-being 0.07 0.00 0.00
Emotional well-being 20.16 20.14 20.15
Functional well-being 20.22* 20.11 20.24**
Lee-Symptom Scale
Energy 20.29** 20.45*** 20.45***
Skin 0.01 0.09 0.06
Nutrition 20.15 20.14 20.10
Lung 20.12 20.15 20.15
Mouth 0.09 0.09 0.04
Psychologic 0.01 20.02 0.00
Eye 20.05 20.02 20.02
HAP indicates Human Activity Profile; AAS, adjusted activity score.
Note: *P < .05, **P < .01, ***P < .001.
Figure 4. Impact of change of cGVHD status on the AAS.
1714 Biol Blood Marrow Transplant 16:1707-1717, 2010P. Y. Herzberg et al.assessment of cGVHD is usually performed within
a time frame of 2 to 6 months and the HAP was
suggested for evaluation of the effect of cGVHD and
its associated immunosuppressive treatment on physi-
cal functioning [13]. The 4 cohorts (no cGVHD
[n5 38], stable cGVHD [n5 52], improved cGVHD
status [n 5 14], and worsened cGVHD [n 5 8]) were
analyzed for their impact on the MAS, AAS, as well
as on the physical functioning scale of the SF36 and
the FACT-BMT total score during 5 months of treat-
ment. Stable cGVHD was defined by no change in the
overall severity of cGVHD, whereas worse cGVHD
was defined by progression from mild to moderate orFigure 3. Impact of change of cGVHD status on the MAS.moderate to severe cGVHD, and improved cGVHD
was defined by reduction of the overall severity of
cGVHD. Although patients with improved cGVHD
status demonstrated an improvement of the MAS
and AAS (mean MAS 74 to 77 and mean AAS 55 to
60), patients with stable cGVHD or worsening of
cGVHD had a decline in their activity scores. Patients
with stable cGVHD had a mean decline of 3 points of
the MAS (73 versus 70) whereas the AAS showed only
an insignificant decline (mean 54.1 versus 53.7). Pa-
tients with worsened cGVHD had a decline of activity
scores (mean MAS 76 versus 72, mean AAS 61 versus
57) during a 5-month period. Patients without
cGVHD demonstrated a mild increase of the MAS
(mean 71 to 73) and AAS (mean 55.7 to 56.3). We fur-
ther evaluated the decline of the MAS and AAS with
log-linear analyses (SPSS GENLOG). The tested
model revealed a good fit to the data (Likelihood ratio
4.86, df 5 4, P . .05). It indicates that the decline of
the MAS and AAS in patients with stable cGVHD
was significantly associated with a increase of mildFigure 5. Impact of change of cGVHD status on the physical function-
ing subscale of the SF36.
m
e
a
n
 F
AC
T-
BM
T 
to
ta
l s
co
re
0,0
0,5
no c
GVH
D
no c
hang
e of c
GVH
D
progr
essio
n of c
GVH
D
impro
veme
nt of 
cGVH
D
1,0
1,5
2,0
2,5
3,0
3,5
T1
T2
Figure 6. Impact of change of cGVHD status on the FACT-BMT total
score.
Figures 3-6. Mean MAS (Figure 3), AAS (Figure 4) of the HAP and
Physical functioning subscale of the SF36 (Figure 5), and FACT-BMT total
score (Figure 6) in correlation to the change of the overall severity of
cGVHD (stable cGVHD [n5 52], improved cGVHD [n5 14], and pro-
gressive cGVHD [n5 8]) versus patients without cGVHD (n5 38). T1
refers to the time of inclusion, whereas T2 refers to evaluation 4-5
months after inclusion.
Biol Blood Marrow Transplant 16:1707-1717, 2010 1715Human Activity Profile after Hematopoietic Stem Cell Transplantationsteroid-myopathy (Z 5 214.1, P\ .001). In contrast
to the results of the HAP, the physical functioning sub-
scale of the SF36 detected no changes in the group
with stable (mean 43.5 to 43.9) and worsened cGVHD
(patients improved with a mean subscore from 44 to 47
despite progression of cGVHD). In line with the HAP
results, the group of responding cGVHD showed sig-
nificantly improved (mean 35 to 48, P\0.05) physical
functioning subscores during a 5-month period. Dur-
ing the same time frame patients without cGVHD
showed an increase of the mean physical functioning
subscore of the SF36 (47 to 49). With regard to the
FACT-BMT total score there was no significant
change for any of the 4 groups (Wilks l 5 0.99, P\
.05). The impact of change of the cGVHD status on
the AAS, MAS, and physical functioning subscale is
shown in Figures 3-6.DISCUSSION
Physical functioning is of major importance for the
QOL after alloHSCT as demonstrated by the presented
data as well as by a numberof studies [26-28]. AlloHSCT
as well as aGVHD and cGVHD leads to impairment of
physical functioning [4,27,29-33]. To quantify the effect
of cGVHD and the related immunosuppressive
treatment on physical functioning, several tools like the
Stanford 7-day recall questionnaire, the HAP, and the
SF36 have been used [8,17,34,35]. Although the SF36
contains 10 questions on physical activity that cover
broad concepts of physical functioning, the HAP
contains 94 items that allow detailed coverage ofphysical activities over a broad range partly not covered
by the SF36. Moreover, the HAP questions detect
the loss of physical function, whereas the SF36 inquires
only about activities being currently performed.
Consequently, the NIH consensus conference on
cGVHD suggested the SF36 and HAP for
measurement of physical functioning [13]. Although
our study used the German language HAP, we believe
our results are generalizable to the English version as
well because the psychometric testing of the German
version of the HAP as well as convergent validity
revealed comparable results to the English version.
The results show that the MAS scores have high in-
ternal consistency, although the test-retest correla-
tions for MAS and AAS scores for successive
monthly time intervals were lower compared to prior
studies. Lower test-retest correlations may be because
of actual variations in activity over the monthly inter-
vals because of cGVHD status or side effects of treat-
ment such as steroid-myopathy [36-38]. The low
corrected item-scale correlation for the first 6 items
(eg, listening to the radio, standing) is explained by pa-
tient selection because all patients were included after
3 months posttransplantation, and the majority were
outpatients able to perform these activities.
Consistent with the literature, we observed a close
correlation of the HAP with the physical domain of
the SF36 [12,39,40]. However, there was no clear
relationship between the physical functioning subscale
of the SF36 and change in the cGVHD status besides
significant improvement in patients with resolving
cGVHD. Likewise, the FACT-BMT did not correlate
with changes of the cGVHD status. In contrast,
changes in the HAP score correlated both with
improved and worsened cGVHD, indicating that the
HAP may be more sensitive than the SF36 to changes
in the cGVHD status. Other results suggest that the
HAP is more sensitive than the SF36 and the FACT-
BMT to the presence of toxicity because of immunosup-
pression such as steroid-myopathy.
We did not find a correlation with symptom burden
or social functioning or social well-being. Moreover, no
correlation was detectable with personality, age, and sex,
indicating that the HAP may serve as a reliable indepen-
dent tool measuring the impact of severity of cGVHD
and side effects of immunosuppression on physical func-
tioning. This is in line with other studies demonstrating
a significant impact of cGVHD on the functional status
[41,42]. No impact of symptomatic osteoporosis,
osteonecrosis, and daily muscle cramping on physical
functioning was detectable, which may be explained in
part by the low number of patients involved and their
heterogeneity. Interestingly, anxiety and depression
moderately correlated with both HAP scores suggesting
that studies using physical functioning as a secondary
endpoint should also include a questionnaire measuring
anxiety and depression. Whether depression precedes
1716 Biol Blood Marrow Transplant 16:1707-1717, 2010P. Y. Herzberg et al.inactivity or inactivity leads to depression in cancer
patients remains to be evaluated [29,43-45].
The evaluation of activities on the HAP that are
prohibited in patients receiving immunosuppressive
therapy revealed that a significant proportion of pa-
tients answered these questions with ‘‘stopped doing
this activity,’’ which was not explained by the physical
functioning indicated by a significantly higher MAS.
Engagement in prohibited activities increased after 1
year, indicating the return to daily activities performed
prior to transplantation in some patients despite the
presence of cGVHD. Therefore, we recommend use
of an ‘‘HSCT-adjusted’’ AAS for evaluation of patients
within 1 year of alloHSCT as well as in patients with
significant immunosuppression afterwards to adjust
for a falsely low AAS.
Because currently the application of the HAP is re-
stricted to adults, pediatric trials require the use of
other questionnaires like the Activity Scale for Kids
questionnaire and the Pediatric Quality of Life mea-
sure (PedsQL), which are currently validated within
a trial of the German-Austrian Pediatric Working
Group on stem cell transplantation [46,47].
In summary, we demonstrated high internal con-
sistency of HAP and good correlation of MAS and
AAS with cGVHD severity. In contrast to physical
functioning domains of other commonly used instru-
ments, the HAP also demonstrated good sensitivity
to change, suggesting its utility as an indirect measure
of therapeutic response in cGVHD clinical trials. The
improvement of the MAS and AAS in patients without
cGVHD indicates that patients recover with time un-
less cGVHD and treatment related effects intervene
[48]. Because the presented study did not include ob-
jective functional measures such as 2- or 6-minute
walk tests, further studies are required to evaluate the
relationship between functional tests and the HAP,
which is currently ongoing. Furthermore, the perfor-
mance of the HAP should also be evaluated as an end-
point in randomized clinical trials, and as a predictor of
long-term outcomes.ACKNOWLEDGMENTS
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